Eli Lilly sidelines midstage prospect in another pain pipeline pivot – Fierce Biotech

Lilly had been putting the asset through its paces in osteoarthritis, diabetic neuropathic pain and chronic back pain as part of the Big Pharma's …
Source: back pain